Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients